Deep Tech Startups

Cyclicor is a deeptech material science company developing isocyanate-free and biobased polyurethanes. Its polymer materials are used for adhesives (hotmelt and liquid), coatings, elastomers, TPU, and foam.

1 investor

Cycuity provides Radix security analysis and verification tools that detect security weaknesses in semiconductor designs, from IP blocks and RTL to full SoCs with firmware. It serves semiconductor manufacturers and defense, automotive, and data center hardware developers seeking to prevent chip vulnerabilities and achieve compliance.

1 investor

CyGenica develops GEENIE, an engineered protein nanoneedle for intracellular drug delivery that bypasses endosomes to deliver therapeutic molecules such as nucleotides and proteins directly inside cells. The technology targets treatments for cancers and rare disorders and is offered to biopharmaceutical partners.

1 investor

Cyndr offers a capability intelligence platform that maps organisations, research activity, and technologies across national security and emerging technology ecosystems. It helps investors—including venture capital firms, strategic investors, and government-backed innovation funds—discover emerging companies, evaluate technology relevance, and monitor developments across defence, intelligence, and national security domains.

1 investor

Cytochroma provides genetically diverse iPSC-derived human cell models, high-throughput screening, and phenotypic data (branded "Wet AI") for drug discovery and preclinical validation. It serves pharmaceutical and biotech teams seeking donor-matched, multi-lineage cell panels across diverse populations to support safety, efficacy, and regulatory testing.

1 investor

Cytomos develops AuraCyt®, a microelectronics-based biotechnology platform for real-time single-cell analytics in bioprocessing and cell and gene therapy manufacturing. The company serves large biotech and pharma companies seeking cost-effective process analytical technology solutions for drug development and manufacturing.

1 investor

Cyto Recovery develops technology for label-free cell sorting and gentle sample cleanup for cell populations, aimed at life-science and research users. Its products are positioned as tools for separating and purifying cells without labeling.

1 investor

Hone Bio is a pre-clinical biotech company developing NanoPilot lipid nanoparticle (LNP) targeting technology for extrahepatic drug delivery, engineering LNPs to target specific cell types while blocking off-target liver uptake. It serves therapeutic developers seeking to deliver treatments such as mRNA-based therapies beyond the liver.

1 investor

D-Fend Solutions develops radio frequency and cyber-takeover technology to address counter-drone and air defense challenges. The company partners with organizations in the UAS, cybersecurity, and defense sectors to deploy its flagship platform.

1 investor

D-Wave is a quantum computing company building both annealing and gate-model systems, offering the Leap quantum cloud platform, hybrid solvers, and Ocean developer tools. It serves enterprises and researchers tackling optimization, simulation, and modeling problems, and also provides professional services, training, and quantum AI solutions.

1 investor

D2B3 develops proprietary drug delivery technology that temporarily relaxes the blood-brain barrier to enable therapeutic targeting of central nervous system diseases. The platform is designed to work across multiple drug classes for treating brain-related disorders.

1 investor

Da Capo develops therapies aimed at halting the progression of neurodegenerative disease, using a target and drug discovery platform that combines data analytics, network biology, human iPS cell models, and chemistry and phenotypic screening. It focuses on recapitulating human neurodegenerative biology to identify disease drivers and move from target to lead compound.

1 investor

DalCor Pharmaceuticals is a biopharmaceutical company developing dalcetrapib, a pharmacogenetic precision medicine for cardiovascular disease that targets patients with the ADCY9 AA genotype. The drug is being evaluated in Phase 3 clinical trials to reduce fatal and non-fatal myocardial infarction in post-acute coronary syndrome patients.

1 investor

Dali Wireless develops digital radio distribution systems and digital predistortion technology, holding a portfolio of over 500 patents covering RF distribution, power amplifiers, and software-defined networking that enable 4G, 5G, and virtual Radio Access Network (vRAN) deployments. Its intellectual property is licensed to mobile operators, large enterprises, and public safety networks for in-building wireless, urban densification, rural coverage, and RAN virtualization.

1 investor

Dalriada Drug Discovery provides early-stage drug discovery and development services, including platform technology development, biochemical assays, and medicinal chemistry support for biotech and pharmaceutical companies. The company serves clients across oncology, infectious disease, immunomodulation, and other therapeutic areas, with expertise in hit identification, lead optimization, and preclinical candidate nomination.

1 investor

Damae Medical develops deepLive, a non-invasive skin imaging system based on LC-OCT (Line-field Confocal Optical Coherence Tomography) that produces 3D histology-like and confocal-like images of skin tissue. The device is used by dermatologists to image and assess skin conditions including melanoma and carcinoma.

1 investor

Shitong Microelectronics designs and develops machine-vision sensing chips, with a focus on high-precision, low-power, cost-competitive 3D sensors based on SPAD dToF technology. It is a semiconductor startup serving machine-vision and 3D-sensing applications.

1 investor

Daqstra builds software infrastructure for observability and orchestration of physical systems, enabling teams to manage data acquisition, configuration, and real-time operations from test environments and hardware deployments. The platform serves engineering teams operating test cells, propulsion systems, and other physical infrastructure that require unified data management and monitoring.

1 investor

Dark Blue Therapeutics develops novel medicines for cancer through integrated drug discovery combining internal expertise with academic partnerships. The company focuses on identifying transformative therapeutic approaches across multiple cancer mechanisms.

1 investor

DarkVision builds ultra-high-resolution 3D inspection technology for industrial asset integrity, using ultrasound hardware with dense 2D arrays, proprietary silicon chips, and machine learning to detect and quantify defects in critical infrastructure. It serves industrial operators evaluating asset integrity problems.

1 investor

DataMesh builds digital twin and XR (AR/VR) technology to support frontline workers with technical training, safety, and real-time 3D collaboration. Its FactVerse platform provides enterprises with tools for spatial data processing and 3D visualization, used in applications such as BIM-based building visualization.

1 investor

DataMesh provides an industrial digital twin platform that combines 3D visualization, real-time data integration, simulation, and AI agents to enable operational decision-making for manufacturing, construction, facility management, and logistics teams. The platform includes tools for work instruction authoring, facility operations management, and synthetic data generation for physical AI development.

1 investor

Gilat DataPath builds satellite communications (SATCOM) equipment and network management software, including its MaxView management platform and DKET terminal systems, for commercial and military users operating in remote locations. It also provides technical support, field services, and sustainment/repair services for critical communications networks.

1 investor

Datarock develops machine learning solutions that transform mining data—including downhole, airborne, and satellite datasets—into geoscientific insights to support exploration and mining operations across the value chain.

1 investor